Patient monitoring & life support products segment revenues increased 19.9% to $82.8m from $69.1m in the second quarter of 2009.

In-vitro diagnostic products segment revenues increased 8% to $43.2m from $40m in the second quarter of 2009.

Medical imaging systems segment revenues increased 1.9% to $42.7m from $41.9m in the second quarter of 2009.

Second quarter 2010 gross profit was $104.4m, a 14.1% increase from $91.6m in the second quarter of 2009.

Operating income was $47.5m, a 21.9% increase from $39m in the second quarter of 2009 and 49% increase from $31.9m in the first quarter of 2010.

Net income increased 28.1% year-over-year to $42.3m from $33m in the second quarter of 2009.

Xu Hang, chairman and co-chief executive officer, said: “We are happy to report a 12% year-over-year increase in revenues, driven primarily by this quarter’s accelerated international sales growth of 27%.”

“We are particularly encouraged by the accelerated growth we have seen in both emerging and developed markets. Both Latin America and the CIS region led growth among all regions while Western Europe and the US recorded double-digit growth. In China, non-tender sales also continued to expand, growing 19% sequentially and 9.1% year-over-year.

“We also remain committed to our investment in international channels and the localization efforts of our on-site operations. We believe this approach should position Mindray well to continue its strong performance in emerging markets and benefit from new opportunities in both high-end product segments and developed markets.”